Here's why Sucampo paid $200M for its PhIII Niemann-Pick drug
Investigators have outlined the results of a small, single-arm study of a new drug for Niemann-Pick type C disease which inspired a $200 million …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
